Recent advances in systemic treatments for ovarian cancer

Abstract Ovarian cancer remains the leading cause of death from gynaecological cancer. Advances in surgical and chemotherapeutic strategies have led to improvements in outcome. However, the majority of women present with advanced disease with little prospect for cure. In this article, we summarize the systemic management and ovarian cancer and raise a number of important issues: namely the timing of systemic therapy in relation to surgery, the selection of patients who do not require systemic therapy and the development of novel agents.

• Publication year

  2012

• Venue

  Cancer Imaging

• Publication date

  2012-09-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1102/1470-7330.2012.9002PMID 23022887PMCID 3460563
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation.

  2012cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• Incorporation of bevacizumab in the primary treatment of ovarian cancer.

  2011cited by this paper
• A phase 3 trial of bevacizumab in ovarian cancer.

  2011cited by this paper
• OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

  2010cited by this paper
• Making the best of PARP inhibitors in ovarian cancer

  2010cited by this paper
• Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.

  2010cited by this paper
• Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

  2009cited by this paper
• The future of targeted therapies in ovarian cancer.

  2009cited by this paper
• Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

  2009cited by this paper
• Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

  2009cited by this paper
• Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

  2008cited by this paper
• Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

  2007cited by this paper
• Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).

  2007cited by this paper
• Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

  2007cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

  2006cited by this paper
• Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

  2006cited by this paper
• Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.

  2004cited by this paper
• International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma.

  2003cited by this paper
• International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.

  2003cited by this paper
• Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

  2003cited by this paper
• Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.

  2002cited by this paper
• Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr

  2001cited by this paper
• Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

  2000cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper

• Combined Intraperitoneal and Systemic Chemotherapy for Peritoneal Metastases: Drug Delivery Concepts, Pharmacokinetics, and Clinical Applications: A Narrative Review.

  2026cites this paper
• Progesterone Enhances the Sensitivity of Ovarian Cancer Cells to Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Suggesting a Role for Transcription-Replication Conflict-Related Pathways: An In Vitro Study.

  2026cites this paper
• Demographic trends in mortality due to ovarian cancer in the United States, 1999-2020

  2025cites this paper
• The compositional behavior of the human T cell receptor repertoire in ovarian cancer compared to healthy donors

  2025cites this paper
• Ovarian cancer is detectable from peripheral blood using machine learning over T-cell receptor repertoires

  2024cites this paper
• Forced Vasohibin‐1 Expression Increases Paclitaxel Sensitivity of Ovarian Cancer by Inhibiting Microtubule Activity

  2024cites this paper
• The role of non‐genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death

  2023cites this paper
• Knockout of vasohibin‐2 reduces tubulin carboxypeptidase activity and increases paclitaxel sensitivity in ovarian cancer

  2021cites this paper
• Role of long non-coding RNA SNHG1 in occurrence and progression of ovarian carcinoma.

  2018cites this paper
• Farletuzumab in the treatment of ovarian cancer

  2016cites this paper
• ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers

  2014cites this paper
• Small victories add up to paradigm shifts for hard-to-treat tumors

  2014cites this paper
• G-1: new potential therapeutic option for ovarian cancer

  2013cites this paper
• In vivo delivery of siRNA targeting vasohibin‐2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer

  2013cites this paper